Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 2022-11-16 21:00
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement 2022-05-18 20:00
BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission 2021-09-28 20:00
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins 2021-09-23 15:00
Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration 2021-09-07 20:00
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans 2021-08-03 20:00
BioVaxys Announces Non-Brokered Private Placement 2021-06-29 10:46
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study 2021-06-01 20:00
BioVaxys Announces Appointment of Policy Advisor 2021-05-20 20:00
Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day 2021-04-20 20:00
BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology 2021-04-14 20:00
BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T 2021-03-31 20:00
BioVaxys Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins For Its SARS-CoV-2 Vaccine And COVID-T™ Immunodiagnostic Programs 2021-03-15 20:00
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production 2021-02-18 21:00
Covid-T™ Clinical Development Program Initiated Regulatory Advisory Group Engaged 2021-01-28 21:46
BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program 2021-01-25 21:00
1